hotspot -WSS

hotspot

author：knowledge 2025-09-03 15:21:23 - browse：946

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Decaf coffee targeted by food safety group under obscure FDA rule

WSS

Why doctors need education on FDA device approval process

eGenesis tests gene

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Vertex Pharmaceuticals may move headquarters in Boston

Decaf coffee targeted by food safety group under obscure FDA rule

Independent physicians launch a new lobbying group

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

knowledge

ChatGPT in medicine: STAT answers readers' burning questions

Readout LOUD podcast: mifepristone case, GLP

After affirmative action ruling, medical educators look to 'holistic review'

Why the world’s most expensive drug might be worth the price

Drug repurposing or repositioning? The language matters

Will generative AI in health care meet the fate of IBM's Dr. Watson?

After affirmative action ruling, medical educators look to 'holistic review'

Covid vaccine financial winners and losers, from Pfizer to Novavax

Supreme Court strikes down use of affirmative action

Vertex Pharmaceuticals may move headquarters in Boston

explore

The tragedy of Johnson & Johnson’s Covid vaccine

Readout Newsletter: Merck, J&J, and long Covid

Readout Newsletter: Merck, J&J, and long Covid

Medicare Advantage today, explained in one chart

Vertex Pharmaceuticals may move headquarters in Boston

Merck drug for rare lung condition set for approval in U.S.

focus

leisure time

hotspot

focus